BMC Medicine, June 6, 2018
Annelies Wilder-Smith, Kirsten Vannice, Anna Durbin, Joachim Hombach, Stephen J. Thomas, Irani Thevarjan and Cameron P. Simmons
We propose three plausible clinical indications for prophylactic or therapeutic agents against ZIKV. Both vaccines and therapeutics must be evaluated for their efficacy in human trials, yet the design of efficacy trials and the appropriate selection of clinical endpoints pose a challenge. We discuss options on how best to address these hurdles.